Veracyte Inc (VCYT)
NASDAQ:VCYT
Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$33.80
$0.68(1.60%)
At close: 4:00 PM EST
$33.80
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $50.71
Previous CloseN/A
Volume253.49K
Average Volume (3M)989.65K
Market Cap
$3.59B
Enterprise Value$3.37B
Total Cash (Recent Filing)$439.06M
Total Debt (Recent Filing)$39.33M
Price to Earnings (P/E)22.3
Beta1.32
Next Earnings
Aug 11, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume1,085,584
30 Day Avg. Volume989,646
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit8.72
Enterprise Value/Ebitda31.75
Forecast
1Y Price Target
$45.28Price Target Upside33.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)1.82
Revenue Forecast (FY)$586.10M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Reinvestment CapacityA debt-free balance sheet and positive cash flow, combined with improved margins, provide capacity to reinvest in commercial expansion and pipeline launches.
Pipeline ExpansionTrueMRD launch for minimal residual disease in bladder cancer could open a new oncology market by offering panel-free whole genome testing that detects spontaneous mutations.
Test Adoption And Revenue MomentumStrong growth in Decipher and Afirma test volumes reflects rising physician adoption and supports continued revenue expansion.
Bears Say
Analyst Caution On CommercializationAnalyst hold recommendations reflect a need for clearer evidence of sustained long-term growth and successful commercialization of pipeline tests before upgrading to a buy stance.
Execution And Timing UncertaintyOngoing product transitions and multiple planned test launches introduce execution risk and uncertain timing for when pipeline tests will contribute meaningfully to revenue.
Valuation RiskCurrent share valuation appears to incorporate much of the company's long-term growth expectations, which could limit upside potential for investors.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.61 and its highest was $50.71 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $3.59B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Aug 11, 2026 which is in 77 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.334 by $0.186.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.44.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.334. Following the earnings report the stock price went up 24.932%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.28 (33.97% Upside)
$45.28 (33.97% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.34%
12-Months-Change
Fundamentals
Return on Equity
6.86%
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$45.28
▲(33.97% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.81% Insiders
34.98% Mutual Funds
24.09% Other Institutional Investors
1.60% Public Companies and
Individual Investors